The mRNA vaccine development landscape for infectious diseases

An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization

“…Therefore, mRNA-LNP immunization may be a more effective strategy to quickly produce mAbs against such targets. The COVID-19 pandemic has accelerated the research toward mRNA technologies ( Kumar et al, 2022 ), and the success of mRNA-LNP vaccines suggests that the technology may be efficiently applied for the rapid development of high-quality mAbs against SARS-CoV-2 and other pathogens. In this study, we demonstrated this potential by using RBD mRNA-LNP as a novel immunogen for hybridoma-based mAb production.…”

An Efficient Approach for SARS-CoV-2 Monoclonal Antibody Production via Modified mRNA-LNP Immunization

“…Therefore, mRNA-LNP immunization may be a more effective strategy to quickly produce mAbs against such targets. The COVID-19 pandemic has accelerated the research toward mRNA technologies (Kumar A, et al, 2022), and the success of mRNA-LNP vaccines suggests that the technology may be efficiently applied for the rapid development of high-quality mAbs against SARS-CoV-2 and other pathogens. In this study, we demonstrated this potential by using RBD mRNA-LNP as a novel immunogen for hybridoma-based mAb production.…”

“…However, preparation of traditional protein antigens is often the most critical and time-consuming step in the mAb production process, especially for mAbs against hard-to-express andpurify antigens like membrane proteins, glycoproteins or conformational epitopes.Therefore, mRNA-LNP immunization may be a more effective strategy to quickly produce mAbs against such targets. The COVID-19 pandemic has accelerated the research toward mRNA technologies(Kumar A, et al, 2022), and the success of mRNA-LNP vaccines suggests that the technology may be efficiently applied for the rapid development of high-quality mAbs against SARS-CoV-2 and other pathogens. In this study, we demonstrated this potential by using RBD mRNA-LNP as a novel immunogen for hybridoma-based mAb production.…”

Saúde humana e os desafios globais das doenças crônicas e infecciosas

“…It is further estimated that approximately 140 mRNA vaccines are currently being developed, 76% in the preclinical stage and 24% in the clinical stage (Chaudhary et al, 2021;Kumar et al, 2022). The latter include vaccines against infectious diseases (Zika virus,chikungunya,malaria,influenza A and B,Ebola,rabies,cytomegalovirus,HIV,respiratory syncytial virus, and various types of cancer (breast, ovarian, colorectal, cervical, lung, liver, pancreas, prostate, solid tumors, melanoma and gastrointestinal neoplasm).…”

“…Estima-se ainda que estão atualmente em desenvolvimento cerca de 140 vacinas de mRNA: 76% em fase pré-clínica, e 24% em fase clínica (Chaudhary et al, 2021;Kumar et al, 2022). Estas últimas incluem vacinas contra doenças infecciosas (Zika vírus, chikungunya, malária, influenza A e B, ebola, raiva, citomegalovírus, HIV, vírus sincicial respiratório, SARS-CoV-2) e contra vários tipos de câncer (mama, ovário, colorretal, cervical, pulmão, fígado, pâncreas, próstata, tumores sólidos, melanomas e neoplasias do sistema digestivo).…”